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INTRODUCTION
The endothelium is a functional barrier between vessel wall 
and blood stream that for a long time has been regarded 
as a relatively inert container for blood [1]. However, the 
last 20 years, researchers have found an extraordinary 
variety of important endothelial functions, including 
control of coagulation, fibrinolysis, vascular tone, growth, 
and immune response. It is now clear that dysfunction 
of the endothelium disturbs the physiological protective 
regulatory balance and could be associated with increased 
mortality in patient with different diseases including com-
munity-acquired pneumonia (CAP) [2, 3].
CAP is one of the most common causes of mortality 
among other infectious diseases all over the world. The 
mortality rate of patients with CAP depends on the severity 
of the disease and comorbidity [4]. Therefore, the early 
identification of patients at risk of serious complications 
is critical to the management of CAP. To improve the 
outcomes in the management of CAP, there has recently 
been a significant attention paid to evidence-based scor-
ing systems and biological markers. They can objectively 
help to predict the severity, to justify hospital or ICU ad-
mission [5]. The role of inflammatory markers has been 
already established rather good. Researchers believe that 
some coagulation and thrombotic disorders during severe 
CAP could lead to some intravascular disorders and even 
be the reason of lethal end in hospitalized patients with 
CAP [6]. The perfect severity score and biomarker does 
not yet exist. There are limited data on the relationship 
between the severity of community-acquired pneumonia 
(CAP) and biomarkers of inflammation and coagulation as 
well [7, 8]. At present, the combination of biomarkers and 
clinical scores has shown promising results in predicting 
mortality and severe outcomes in CAP.
THE AIM
The aim was to evaluate the association between the se-
verity of CAP (according to SMRT-CO score) and risk of 
thrombosis (according to Padui score) in patients with 
moderate and severe CAP. And furthermore, to estimate 
the role of parameters of systemic inflammation (C-reactive 
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protein (CRP), fibrinogen), endothelial dysfunction (endo-
thelin 1 (ET-1)), hemostasis (protein C (PC)), fibrinolysis 
(D-dimer (DD) on different phases of treatment.
MATERIALS AND METHODS 
The main group was 75 patients with moderate to severe 
CAP. Depending on the severity all patients of the main 
group were divided into 2 subgroups: subgroup 1 – 41 
patients with moderate CAP (the mean age was 48.0 [33.0–
61.0] years old, men – 33 (80.0%)), subgroup 2 – 34 pa-
tients with severe CAP (the mean age was 56.0 [46.0–60.0] 
years old, men – 22 (65.0%). Subgroups had no significant 
difference according to age (p=0.178) and sex (p=0.166). 
The formulation of diagnosis CAP and assessment of its 
severity were determined according to the international 
guidelines [4] and SMRT-CO scale [9].
General clinical analysis, blood coagulation test, deter-
mination of biomarkers was performed at admission before 
starting of antibacterial treatment (visit 1) and after clinical 
stability on 7–10 day after hospitalization (visit 2).
DD and CRP levels were estimated by immunoturbodi-
metric method [10, 11], ET-1 was estimated by immuassay 
test, activity of PC was established with optic method [12, 13].
The study was conducted according to Helsinki declaration 
with the permission of the Bioethical commission Dniprope-
trovsk medical academy of the ministry of Health of Ukraine. 
Received results were compared with values in control 
group. The control group was 16 healthy people (the mean 
age was 56.0 [52.0–69.0] years old, men – 13 (81.0%)).
The risk of thrombosis was estimated with the help of 
Padua Prediction Score for risk of lung thrombosis [14].
At died patients we observed autopsy data including 
electronic microscope investigations.
Statistical processing of the results in research was carried 
out using the methods of biometric analysis, implemented 
in software packages EXCEL-2003 (№ 74017-641-9475201-
57075) and STATISTICA 6.0 (№ 31415926535897) [15].
RESULTS AND DISCUSSION
Analyzing the data of main group patients, we detect that during 
hospitalization everybody has clinical symptoms of CAP com-
bining with mono- or bilateral lung infiltration on chest X-ray.
The severity according to the SMRT-CO scale of patients 
in subgroup 1 was 0.0 [0.0–1.0] scores, in subgroup 2 was 
3.0 [3.0–5.0] scores (p=0.000), which proved the right distri-
bution of patient among subgroups.
During investigation of systemic inflammatory markers on 
visit 1, we found that in both subgroup 1 and subgroup 2 the 
mean levels of CRP and fibrinogen were higher than in control 
group (table I). Detailed analysis showed that patients with 
severe CAP had significantly higher levels of CRP (197.6 [147.8–
311.7] mg/l in subgroup 2 comparing with 126.7 [68.7–192.0] 
mg/l in subgroup 1, p=0,000), which reflects the severity of 
inflammation in patients with CAP. The level of fibrinogen did 
not differ between subgroups and was 7.3 [3.7–13.3] mcg/ml in 
subgroup 1 and 7.8 [5.5–12.2] mcg/ml in subgroup 2 (p=0.483).
During investigation of parameters of endothelial function 
(ET-1), hemostasis (PC) and fibrinolysis (DD) we found that in 
both subgroup 1 and subgroup 2 the mean level of DD was sig-
nificantly higher and PC was significantly lower in comparing 
with the mean levels of these parameters in control group, but 
the result of ET-1 depended on the severity of the CAP. Detailed 
Table I. Levels of systemic inflammation parameters in patients with moderate to severe CAP, Me [25-75%]
Parameter Main group Control group p
CRP, mg/l 168.6 [102.6–277.3] 4.5 [3.4–5.5] 0.002
Fibrinogen, mcg/ml 6.8 [4.7–12.2] 2.7 [2.4–3.0] 0.000
Table II. Levels of parameters of endothelial dysfunction, hemostasis and fibrinolysis in patients with moderate to severe CAP, Me [25-75%]
Parameter Main group Control group p
ET-1, ng/ml 0.64 [0.4–1.86] 0.77 [0.45–1.03] 0.778
PC, % 75.0 [64.0–95.0] 95.0 [83.0–105.0] 0.008
DD, ng/ml 1561.2 [989.4–5325.3] 267.0 [254.0–1298.0] 0.000
Table III. Levels of systemic inflammation and coagulation parameters in patients with moderate to severe CAP, Me [25-75%]
Parameter
Visit 1 Visit 2
Control group
subgroup 1 subgroup 2 subgroup 1 subgroup 2
CRP, mg/l 126,7 [68,7–192,0]*#^ 197,6 [147,8–311,7]*#^ 10,6 [5,0–19,2]*#^ 49,0 [6,6–93,0]*#^ 4,5 [3,4–5,5]
ET-1, ng/ml 0,5 [0,36–0,81]*^ 1,4 [0,41–2,5]*#^ 0,6 [0,4–0,7]*^ 1,1 [0,7–2,4]*#^ 0,77 [0,45–1,03]
PC, % 80,0 [68,0–95,0] #^ 70,0 [63,0–95,0]#^ 101,5 [88,5–115,0]^ 106,5 [80,0–135,0]^ 95,0 [83,0–105,0]
Notes: * – p < 0.05 between subgroups on Mann-Witney;
# – p < 0.05 with control group on Mann-Witney;
^ – p < 0.05 between visits on Wilkoxon.
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analysis showed that patients with severe CAP had significantly 
higher levels of ET-1 and the lowest level of PC (table II, table 
III). This fact shows the highest risk of thrombosis in patients 
with severe CAP.
Additionally, the mean level of scores by Padua scale in 
patients with severe CAP was 5.0 [5.0–6.0] scores, which was 
significantly higher than in patients with moderate CAP, who 
had 1.0 [1.0–2.0] scores (p=0.000).
All patients received guided-based antibacterial treatment 
and mucolytic. On the visit 2 which was on 7–10 day after hos-
pitalization most of them had signs of clinical stability: normal-
ization of the temperature, decreasing of cough and dyspnea. 
The proving of general positive effect of treatment is demon-
strated by great decreasing of mean level of CRP in both patients 
with severe and mild CAP (table III). However, it was still dif-
fering from normal value in control group, which shows that 
stabilization of this marker is rather long process.
Regarding ET-1, the mean level of which was increased 
only in severe patients on visit 1, also significantly decreased 
on visit 2, but nevertheless it was still differing from the corre-
sponding parameter in control group. This fact demonstrates 
that endothelial dysfunction which is one of the pathogenetical 
mechanisms of severe pneumonia presents its role during rather 
prolonged time (more than 7–10 days’ period). 
Opposite situation was with nature anticoagulant PC. The 
mean level of this parameter not only significantly increased till 
the visit 2 but also normalized and didn’t differ from the mean 
level of PC in healthy persons on the 7–10 day.
CONCLUSIONS
1.  In-patient cases of CAP are characterized by systemic 
inflammation, which comes out in intensive increasing 
of CRP and hypercoagulation which comes out in de-
creasing of PC, increasing of DD and fibrinogen.
2.  Patients with severe CAP have the high risk of throm-
bosis which can be associated with endothelial dysfunc-
tion and manifested in maximal scores by Padua scale, 
the highest levels of ET-1 and the lowest level of PC.
3.  Normalization of PC is coming after 7–10 days of antibacte-
rial treatment of CAP, vice versa ET-1, which reflects prolong 
endothelial dysfunction in patients with severe CAP.
4.  Definition of such parameters as ET-1 and PC can be 
useful for establishment of different coagulant disorders 
in patient with mild and moderate CAP, and their dy-
namic changes could be the initial point of prescribing 
or cancelling of anticoagulant treatment.
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